RxDoctor Payments Data

Alexandria Jernberg, OD

Optometrist · Eugene, ORNPI 1013501220

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,000 of the $5,659 with a category attached, or 88.4%. Rxsight Inc accounts for 90.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $5,330 and has fallen 96.1% since, to $210 in 2025. Among optometrist clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,659in general payments, 2019–2025

Across 23 payments — averaging $246.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Rxsight Inc$5K
  • Glaukos Corporation$121
  • AbbVie$101
  • Alcon$92
  • Bausch & Lomb Americas Inc.$59
  • Dompe US, Inc.$45
  • plus $99 from 4 others

What the payments were for

  • Consulting fees$5,00088%
  • Food & beverage$65912%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,659 in reported general payments places this provider in the 95th percentile of 684 optometrist providers in Oregon.

See all optometrist providers in Oregon

Medicare billing

Part B allowed, 2024
$46,505
Medicare patients
245
Services billed
527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine21$21,127
Latanoprost383$3,601
Cyclosporine18$3,460
Brimonidine Tartrate44$2,119
Timolol Maleate130$1,462
Prednisolone Acetate19$906
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat47$804
Doxycycline Hyclate19$603
Dorzolamide Hcl19$293
Ofloxacin13$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$101$21,12721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 684 optometrist providers in Oregon.

Other optometrist in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →